Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A cancer and neutropenia database study

A Hewitt1

  • 1Scientific Affairs, Amgen Canada Inc., Mississauga, Ontario.

The Canadian Journal of Oncology
|July 1, 1994
PubMed
Summary

The economic cost of treating cancer patients with febrile neutropenia in Canada was evaluated. Certain patient subgroups may benefit from growth factors like filgrastim, potentially reducing healthcare costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morning compared to afternoon school-based exercise on cognitive function in adolescents.

Brain and cognition·2024
Same author

Linear body measurements and productivity of subtropical Holstein-Friesian dairy calves.

Australian veterinary journal·2020
Same author

Applicability of two bone age assessment methods to children from Saudi Arabia.

Clinical radiology·2019
Same author

Dose-response between frequency of interruption of sedentary time and fasting glucose, the dawn phenomenon and night-time glucose in Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Examination of fatigue development in elite soccer in a hot environment: a multi-experimental approach.

Scandinavian journal of medicine & science in sports·2010
Same author

Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation.

British journal of haematology·2005

Area of Science:

  • Oncology
  • Health Economics
  • Pharmacoeconomics

Background:

  • The economic burden of febrile neutropenia in Canadian cancer patients remains undefined.
  • Filgrastim (Neupogen) is a growth factor used to reduce infection incidence in cancer patients receiving myelosuppressive therapy.
  • Understanding demographic factors influencing treatment costs is crucial for targeted interventions.

Purpose of the Study:

  • To define the economic cost of treating febrile neutropenic cancer patients in Canada.
  • To evaluate the potential economic impact of filgrastim in the Canadian healthcare system.
  • To identify demographic factors influencing treatment costs and potential cost offsets.

Main Methods:

  • A study was commissioned to collect demographic data on cancer and neutropenia patients in Canadian acute care hospitals.
  • A cancer/neutropenia database was created using patient discharge abstracts from the 1990/91 Hospital Medical Records Institute (HMRI) national acute-care hospital database.

Main Results:

  • The study established a database to analyze the costs associated with treating cancer patients experiencing febrile neutropenia.
  • Data analysis aimed to identify demographic factors correlating with treatment costs and hospitalization rates.

Conclusions:

  • The findings support the existence of specific cancer patient subgroups who could achieve clinical benefits and cost savings through growth factor utilization.
  • This research provides a foundation for evaluating the pharmacoeconomic impact of filgrastim and similar agents in Canada.

Related Experiment Videos